Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 5.6% – Time to Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares were down 5.6% during mid-day trading on Monday . The company traded as low as $21.93 and last traded at $21.9050. 678,066 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 1,270,188 shares. The stock had previously closed at $23.21.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CAPR. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. B. Riley Financial raised their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Roth Mkm reaffirmed a “buy” rating and set a $38.00 target price on shares of Capricor Therapeutics in a research note on Friday, May 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Trading Down 5.4%

The firm has a market capitalization of $1.27 billion, a PE ratio of -9.51 and a beta of 0.42. The firm’s fifty day moving average price is $28.87 and its 200 day moving average price is $28.28.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, research analysts expect that Capricor Therapeutics, Inc. will post -0.49 EPS for the current year.

Insider Activity at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the transaction, the chief financial officer owned 8,223 shares in the company, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 50,000 shares of company stock worth $1,551,658. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of CAPR. Goldman Sachs Group Inc. lifted its position in shares of Capricor Therapeutics by 39.5% in the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after buying an additional 116,373 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock valued at $410,000 after acquiring an additional 3,205 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after acquiring an additional 3,636 shares in the last quarter. Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter worth approximately $796,000. Finally, Jump Financial LLC boosted its position in Capricor Therapeutics by 42.6% during the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock worth $2,309,000 after purchasing an additional 69,515 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.